Published in Cancer Weekly, January 26th, 2010
"Therefore, we examined whether mTCR inhibitors synergize with trastuzumab. Immunocompetent mice bearing HER2(+) mammary tumors were treated with trastuzumab, the mTOR inhibitor rapamycin, or the combination. Mice were imaged for tumor cell death using an optical Annexin-V probe and with [F-18] FDG positron emission tomography. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly